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Statement of Translational Relevance
Tamoxifen (Tam) is the most prescribed hormonal agent for the treatment of estrogen receptor (ER) α-positive breast cancer patients. However acquired Tam resistance frequently occurs, but very little is known about mechanisms of resistance. We discovered that Dicer overexpression leads to an increase in the breast cancer resistance protein (BCRP). We demonstrate that BCRP can function to exclude Tam Dicer expression has been shown to be important in maintaining the stem cell population, and in the transition of germ-line stem cells through the G1/S checkpoint (4) (5) (6) . In addition to its role in stem cell proliferation, Dicer is an RNase III-containing enzyme which processes microRNA precursors into mature microRNA able to bind and repress translation, or induce degradation of complementary mRNAs (7) , and microRNAs have been implicated in breast tumor invasion and metastasis (8, 9) . Although a number of investigators have shown a role for breast cancer stem-like and progenitor cells in chemotherapeutic resistance (10) (11) (12) , almost nothing is known about a role for these cells in hormonal therapy resistance. 
Materials and Methods

Reagents, antibodies, and chemicals.
β-Estradiol 3-benzoate and Tam citrate for animal experiments, and 17α-estradiol (E), 4-hydroxy-tamoxifen (T), and fumitremorgin C (FTC or F), Hoechst 33342, and propidium iodide (PI) were from Sigma (St. Louis, MO). MBLI-97 was synthesized as described (13) . Antibodies against BCRP, IRS-1, and Cyclin D1 were from Millipore (Billerica, MA); PR A/B and p85 were from Cell Signaling (Danvers, MA); MDR-1, ERα, and β-actin were from Abcam (Cambridge, MA) Vector Labs (Burlingame, CA), and Sigma, respectively. Antibodies against ERα (confocal), Dicer, Rho GDIα, CD24-FITC, CD44-PE, and MRP1 were from Santa Cruz Biotechnology (Santa Cruz, CA).
Secondary antibodies goat anti-mouse or goat anti-rabbit were obtained from GE Healthcare (Piscataway, NJ). Alexa Fluor 546 goat anti-mouse and 488 goat anti-rabbit secondary antibodies were purchased from Invitrogen (Carlsbad, CA).
Tumor specimens and expression microarray analysis.
A cohort of frozen breast tumor specimens from nine patients who received adjuvant (Tam   S   ) were examined using Affymetrix expression microarray as described previously (2) .
Cells and tissue culture conditions.
MCF-7 parental breast cancer cells were cultured as described (14) . MCF-7 cells stably overexpressing Dicer or vector control plasmid (pcDNA3.1, Invitrogen, Carlsbad, CA) were generated using stable transfection, and supplemented with 800μg/mL Geneticin (Invitrogen). The human Dicer expression vector has been previously described (15 4-hydroxy-tamoxifen. Cells were continuously exposed for 6 months during which time the medium was replaced every 4-5 days (these cells are designated MCF-7 TR2).
Initially cell growth was slow, but gradually increased, and cells have been maintained in Tam for greater than 1 year.
Immunoblot analysis.
After specified treatments, cells were lysed in warm 5% SDS in water or in RIPA buffer containing protease inhibitor cocktail (Calbiochem, San Diego, CA) and sodium orthovanadate (Sigma). Protein concentrations were measured using BCA protein assay (Thermo Scientific, Rockford, IL). Equal amounts of protein extracts were subjected to SDS-PAGE as described (14) .
MTT assay.
Research. 14, the colonies (>50μm) were counted using the Gelcount machine and software (Oxford Optronix, Oxford, UK). Experiments with shRNA to Dicer and BCRP were performed in 5% charcoal-stripped FBS in PRF-MEM.
Flow cytometry.
Secondary mammosphere cells were dissociated with Versene (Invitrogen), and passed through a 40μm sieve (BD Falcon, San Diego, CA) to ensure single cell suspension prior to antibody staining. Cells were resuspended in PBS with CD24-FITC and/or CD44-PE antibodies for 15min at 4°C. The cells were then resuspended in 2% paraformaldehyde at a concentration of 1X10 
Hoechst 33342 efflux assays.
Cells were resuspended in MEM, with 2% fetal calf serum, and 10mM HEPES buffer at a concentration of 1X10 6 cells/ml. Cells were incubated in Hoechst 33342 dye (5ug/ml) for 2hrs at 37°C, then resuspended in HBSS with 2% fetal calf serum, 10mM HEPES buffer containing 2μg/ml PI, and analyzed on a LSRII.
Mammosphere culture.
Mammospheres were grown as described (16). Mammospheres were allowed to grow for approximately 14 days and then they were dissociated enzymatically, and replated to grow secondary mammospheres.
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Tumor xenografts.
All animal studies were carried out according to the guidelines and with the approval of the Baylor College of Medicine Animal Care and Use Committee. Female nude ovariectomized athymic mice, 5-6 weeks old, were obtained from Harlan (Indianapolis, IN). Our preliminary data showed that we could use much fewer cells if cells grown in mammosphere culture were injected, rather than cells grown on plastic (data not shown).
Thus, secondary mammospheres were dissociated and counted on a hemocytometer for injection. Cells in conditioned media were mixed 1:1 with growth factor-reduced PRF matrigel (BD Biosciences), and inoculated s.c. into the 4 th mammary gland as described (2) . Animals were supplemented subcutaneously with silastic tubing releasing 80pg/ml of β-estradiol,3-benzoate. When the tumors grew to ~200mm 3 , estrogen treatment was continued, or the tubing was removed and daily subcutaneous Tam injections were begun. Tumor volumes were measured three times weekly for 4-6 weeks.
Immunofluorescence and confocal microscopy.
Secondary mammospheres were harvested, washed in PBS, and seeded in matrigel:PBS (1:1) solution on 8-well chamber slides. Matrigel was allowed to solidify at 37°C for 30min. Mammospheres were fixed in 2% PFA/PBS (Sigma) for 20min.
Acini were permeabilized with 0.5% TritonX-100/PBS for 10min and then wash three times with 100mM Glycine/PBS. Mammospheres were then blocked with 10% BSA/IF buffer (7.7mM Sodium Azide, 0.1% BSA, 0.2% TritonX-100, 0.05% Tween-20 in PBS) for 1hr. Primary antibody was diluted in 10% BSA/PBS and slides incubated at RT 
shRNA.
Cells were plated in regular growth medium to 60-70% confluence. Then the medium was changed with serum free medium (SFM) without P/S and cells were transfected with 5μg of shRNA empty vectors and shRNA plasmids using Lipofectamine 
Statistical analyses.
All data are expressed as the mean (+/-SD) of at least three independent experiments unless otherwise stated. Unpaired two-sample t-test analysis was used to analyze the differences between the treatment and control groups. Some data was compared using two-way ANOVA testing for a significant interaction between the treatment and cell types. Statistical analysis was performed using R (www.r-project.org) or Red-R (www.red-r.org). P-values were adjusted using the Bonferroni method. L-calc software
was not used to model tumor initiation because our data did not fit the model, so Poisson regression was utilized to model tumor initiation rates in the Dicer-overexpressing (MCF/D15) and vector-control cell groups (MCF/VC1) adjusting for the effect of different serial dilutions.
Results
Dicer overexpression and resistance to Tam.
Research. were generated (MCF/DP1). Parental cells were also stably transfected with a vectoralone plasmid (MCF/VC1), or vector-alone pools were generated (VP1 and VP2) (Fig.   1B) . All of the Dicer-transfected clones expressed higher Dicer protein levels (Fig. 1C) .
To rule out the possibility that loss of ER expression could account for Tam resistance, we performed immunoblot analysis for ERα. ERα expression was maintained in both vector control and Dicer-overexpressing clones, although variable levels of ERα were observed, probably due to clonal variability. As an additional control, we also Dicer clones demonstrating that ERα activity was not altered with Dicer overexpression in MCF-7 cells.
In Drosophila, germ-line stem cell division is regulated by Dicer, and in mammals, proliferation is compromised in Dicer-deficient murine embryonic stem cells (6, 17) . To determine whether Dicer overexpression affects cellular response to Tam resistance, we conducted MTT ( To evaluate the effect of Dicer overexpression on the tumor-initiating population in mammospheres, we performed a limiting dilution transplantation experiment using mammosphere-cultured cells implanted as xenografts into athymic mice. Because mammary tumor initiation in athymic nude mice requires estrogen supplementation, secondary mammospheres from the estrogen supplemented groups were dissociated, and serial dilutions from 10,000 to 2 cells were used for tumor initiation (Supplement Table   1 ). The tumor initiation rate in the MCF/VC1 vector group was 0.40 (95% CI: 0.28 - 
Dicer increases BCRP expression.
We performed immunoblot analysis for proteins associated with drug resistance in Dicer-overexpressing cells (24, 25) (26).
Dicer-overexpressing mammospheres expressed elevated levels of the breast cancer resistance protein BCRP, which was independent of hormone treatment in one-dimensional cultures (Fig. 3A) . Since elevated levels of the BCRP "pump" are known to be associated with resistance to a number of chemotherapeutics (27), we next focused on whether elevated levels may mediate the Tam R phenotype of Dicer-overexpressing cells.
Levels of BCRP protein were also found to be elevated in Dicer-overexpressing cells grown in mammosphere cultures; the MCF/D12 clone exhibited a 4-fold increase, MCF/D15 clone a 4.5-fold , and the MCF/DP1 pool a 3.5-fold increase in BCRP levels ( Fig. 3B and quantified in 3C) . Thus, increases in BCRP expression were not just a consequence of cell culture conditions. The effects of Dicer overexpression on BCRP levels may be at the transcriptional level, since higher levels of BCRP mRNA were also seen in the MCF/D15 clone (Fig. 3D) . Importantly, we found that 3/5 of the Tam R breast tumors initially screened in our microarray analysis (Fig. 1A) also expressed elevated levels of BCRP mRNA, whereas none of the Tam S tumors expressed measureable levels using qRT-PCR assay (Fig. 3E) .
BCRP, along with MDR1 and MRP1, are three of the most studied multidrug resistance proteins. Clinically, a Phase III trial in 99 breast cancer patients found that the combination of the MDR1 inhibitor Verapamil with a chemotherapeutic yielded significantly longer overall survival and a higher response rates than those treated with chemotherapy alone (28). MDR1 was expressed at comparable levels in both cells, but MRP1 was expressed at slightly higher levels in Dicer-overexpressing pools (Fig. 3F) .
We have focused on BCRP in this study, but we have not yet eliminated a role for MRP1 in the phenotype of Dicer-overexpressing cells.
Research. Immunoblot analysis was performed on the sorted NSP and the SP fractions (Fig. 3H ).
The SP of the vector cells contained very few cells (0.2%) and thus BCRP protein levels were undetectable by immunoblot. The SP fraction in the Dicer-overexpressing pool (MCF/DP1) expressed elevated levels of BCRP protein while maintaining Dicer and ERα expression (Fig. 3I) . The SP fraction of MCF/VC1, though low (0.2%, Fig. 3I ), contained high levels of ERα consistent with our data demonstrating that tumor-initiating cells can be ERα-positive.
To further demonstrate that the cells grown as mammospheres expressing BCRP also expressed ERα, we performed immunofluorescence followed by confocal microscopy (Fig. 4) . As expected, MCF/VP1
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on 
Modulation of Tam response by BCRP knockdown and inhibitors.
To confirm the role of BCRP in response to Tam, we first used a specific BCRP inhibitor, MBLI97 (M,(13)) in soft agar assays (Fig. 5A) . Next, MCF/DP1 cells were stably transfected with a shDicer expression vector or a control shRNA vector (Fig. 5B) . All the shDicer clones exhibited a reduction in Dicer expression; BCRP expression was concomitantly reduced in the knockdown clones (Pearson's correlation p=0.00038). Two shDicer clones were used in a soft agar growth assay to test for response to Tam and/or a BCRP inhibitor (Fig. 5C ). Fumitremorgin C (FTC or F), a BCRP inhibitor which inhibits BCRP-related ATPase activity was used 
Discussion
In the present study, we investigated a unique molecular mechanism underlying a 
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